Obesity Clinical Trial
Official title:
Systemic and White Adipose Tissue Inflammatory Profile in Lean Versus Obese Individuals
NCT number | NCT04078776 |
Other study ID # | R19-P144 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 25, 2019 |
Est. completion date | August 1, 2020 |
Verified date | May 2022 |
Source | Loughborough University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will compare the systemic and white adipose tissue inflammatory profile of individuals who are classified as lean and obese. Blood and white adipose tissue samples will be collected in the fasted state to assess inflammatory status. There is evidence to suggest that markers of inflammation in the blood and white adipose tissue increase with increasing levels of obesity. However, the white adipose tissue total protein content and phosphorylation of proteins involved in inflammatory pathways has not previously been compared between lean and obese individuals. The investigators hypothesise that obese individuals will have increased levels of inflammation in the blood and white adipose tissue, compared to their lean counterparts.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 1, 2020 |
Est. primary completion date | August 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - 18-40 years - Waist circumference/BMI criteria: - Lean participants: waist circumference =94 cm (men) and 80 cm (women) and BMI = 21.0 kg/m2 or - Obese participants: waist circumference =102 cm (men) and 88 cm (women) and BMI = 30.0kg/m2 - Recreationally active (> 3 x 30 min moderate exercise per week) - Blood pressure systolic blood pressure <160 mmHg and diastolic blood pressure <100 mmHg Exclusion Criteria: - Smoker (including vaping) - Cardiometabolic or inflammatory disease (e.g. heart disease, high blood pressure, type 2 diabetes) - Taking medication or nutritional supplements (e.g. fish oil/prebiotics) known to interfere with study outcomes (including inflammation, immune function or lipid/carbohydrate metabolism) or prescribed antibiotics within the last 3 months - Unstable weight history (= 3kg loss or gain in previous 3 months) - An allergy to lidocaine (determined by the Schools standard health questionnaire) - Parallel participation in another intervention study - Women who are pregnant or lactating - Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a metabolic study - Alcohol consumption >28 units per week for a man or >21 units per week for a woman |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Loughborough University | Loughborough |
Lead Sponsor | Collaborator |
---|---|
Loughborough University |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Protein expression (content and phosphorylation) of key markers of metabolic inflammation in white adipose tissue (for example assessment of Nuclear factor kappa B (NFKB) total protein and phosphorylation by western blot analysis) | This will be assessed following the collection of fasted white adipose tissue samples | Cross-sectional (all outcome measures will be collected within a 2 week period) | |
Secondary | Systemic Markers of Inflammation (for example C-reactive protein and interleukin 6 concentrations, determined by spectrophotometric assay/ ELISA) | This will be assessed following the collection of fasted white adipose tissue | Cross-sectional (all outcome measures will be collected within a 2 week period) | |
Secondary | Gene expression of key markers of metabolic inflammation in white adipose tissue | This will be assessed following the collection of fasted white adipose tissue | Cross-sectional (all outcome measures will be collected within a 2 week period) | |
Secondary | Characterisation of immune cell populations (monocyte subsets) from peripheral blood mononuclear cells (measured using flow cytometry analysis) | This will be assessed following the collection of fasted blood samples | Cross-sectional (all outcome measures will be collected within a 2 week period) | |
Secondary | Habitual Dietary Intake | This will be assessed following the collection of a 4 day weighed food diary | Cross-sectional (all outcome measures will be collected within a 2 week period) | |
Secondary | Physical Activity | Assessed using Actigraph accelerometers over a 4 day period | Cross-sectional (all outcome measures will be collected within a 2 week period) | |
Secondary | Fasting Serum Markers of Insulin Resistance (for example insulin and glucose concentrations, determined using an ELISA/ spectrophotometric assay) | This will be assessed following the collection of fasted blood samples | Cross-sectional (all outcome measures will be collected within a 2 week period) | |
Secondary | Fasting Serum Lipid Profile (for example total cholesterol, HDL cholesterol and triacylglycerol concentrations, measured using a spectrophotometric assay) | This will be assessed following the collection of fasted blood samples | Cross-sectional (all outcome measures will be collected within a 2 week period) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |